| ²é¿´: 321 | »Ø¸´: 0 | ||
hongyamingÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
һƪ¼ò±¨£ºdoxazosin, (S) Sepracor discontinued, USA.(Brief Article)
|
|
һƪ¼ò±¨£ºdoxazosin, (S) Sepracor discontinued, USA.(Brief Article) ÏêϸÐÅÏ¢£ºdoxazosin, (S) Sepracor discontinued, USA.(Brief Article) Article from: R & D Focus Drug News | February 10, 2003 | Copyright Sepracor is no longer developing the S isomer of doxazosin as a potential treatment for benign prostatic hypertrophy. The product had reached phase I trials. ¡ ÍøÕ¾£ºhttp://business.highbeam.com/436 ... -97769942/doxazosin ÇóºóÃæµÄ±¨µÀÄÚÈÝ¡£ |
» ²ÂÄãϲ»¶
ÖÐɽ´óѧ-µÚÆßÒ½Ôº-ÕпÆÑÐÖúÀí1Ãû£¨»ùÒòÉè¼ÆºÍ¿Ë¡¡¢RNAºÏ³É£©
ÒѾÓÐ1È˻ظ´
°ÍÀèÈø¿ËÀ×´óѧÓë¹ú¼ÒÁôѧ»ù½ðίºÏ×÷²©Ê¿Ñо¿ÉúÏîÄ¿-Ö¬ÖÊÄÉÃ×Ò©Îï/ÉúÎï²ÄÁÏ/¶à·ÓµÝËÍ
ÒѾÓÐ10È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ278È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ0È˻ظ´
½õÖÝÒ½¿Æ´óѧҩÓÃÉúÎï²ÄÁÏ£¨×¨Òµ´úÂë1007Z1£©ÕÐÊÕµ÷¼Á¿¼Éú
ÒѾÓÐ2È˻ظ´
26É격×Ô¼ö
ÒѾÓÐ12È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§¡¢ÉúÎï¼ìÑéÏà¹Ø×¨ÒµµÄÑо¿Éú
ÒѾÓÐ1È˻ظ´













»Ø¸´´ËÂ¥